Logo 1 Logo 2

Clinical Trial Details

Trial ID: L3802
Source ID: NCT03018444
Associated Drug: Atorvastatin
Title: The Effect of HMG-CoA Reductase Inhibition on Postprandial GLP-1 Secretion
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes Mellitus, Type 2|Hydroxymethylglutaryl-CoA Reductase Inhibitors
Interventions: DRUG: Atorvastatin|OTHER: Placebo
Outcome Measures: Primary: Postprandial GLP-1 secretion, 240 min | Secondary: Postprandial Bile Acid Composition, 240 min|Postprandial total plasma Bile Acid, 240 min|Postprandial Glucose Tolerance, 240 min|Postprandial plasma lipid response, 240 min|Postprandial GIP secretion, 240 min|Enteric hormones known to influence glucose metabolism, 240 min|Gallbladder emptying, 240 min|Faecal content of bile acid, One sample collected on day 12 or 13 of the intervention|Gut microbiota composition, One sample collected on day 12 or 13 of the intervention|Gastric emptying, 240 min|Resting Energy Expenditure, At time -20 min, +60 min and +220 min
Sponsor/Collaborators: Sponsor: University Hospital, Gentofte, Copenhagen
Gender: MALE
Age: ADULT, OLDER_ADULT
Phases:
Enrollment: 15
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE
Start Date: 2016-10
Completion Date: 2017-01
Results First Posted:
Last Update Posted: 2017-03-03
Locations: University Hospital, Gentofte, Copenhagen, Hellerup, Region Hovedstaden, 2900, Denmark
URL: https://clinicaltrials.gov/show/NCT03018444